
- Results demonstrate 70% risk reduction for long-term clinical outcomes in patients with Alagille syndrome (ALGS) treated with LIVMARLI (p

- Results demonstrate 70% risk reduction for long-term clinical outcomes in patients with Alagille syndrome (ALGS) treated with LIVMARLI (p
Mirum Pharmaceuticals, Inc. on 6ix
Follow Mirum Pharmaceuticals into a list and get an email when it puts out news.
Follow Mirum Pharmaceuticals